UCrest targets 10pc revenue contribution from genetic test kit

PETALING JAYA: Mobile health platform developer and operator UCrest Bhd is eyeing a 10 per cent revenue contribution from the distribution of BRCATRUE.

BRCATRUE is an early breast and ovarian cancer detection genetic test kit.

In a tie-up with United Statesbased genetic testing specialist Pathway Genomics, UCrest will distribute its products in Southeast Asia, China, Taiwan and Russia.

UCrest chief executive officer Eg Kah Yee said the group was also working to set up Pathway Genomics clinical laboratories overseas.

“We have the technology for genetic testing through saliva swabs, with the results available within two weeks,” he said after the company’s extraordinary general meeting (EGM), here, yesterday.

At the EGM, UCrest received shareholders’ approval for a private placement exercise involving up to 20 per cent of its total share capital.

The company intends to raise up to RM42.76 million for marketing and other business purposes.

Yee said the kit was available at the company and clinics throughout the country.

“We will provide the results in about two weeks and there will be an online physician assigned to you to help understand the results of the test.

“We can send the kit to anywhere in Malaysia. This is an easy option compared to getting a blood test,” he added.

The company is partnering with Pathway Genomics to reduce the need to go to hospitals or clinics for pathological tests. Zarina Zakariah